Creating complex genetically engineered mouse models for biomedical research can be both challenging and time-consuming. In this presentation, Dr. Ouyang examines traditional techniques such as embryonic stem (ES) cell homologous recombination and Targeted Gene Editing-mediated genome editing for developing gene-targeted animal models. He also showcases Cyagen’s extensive collection of ready-to-use knockout (KO) and conditional knockout (cKO) mouse models, all developed using these advanced technologies.

A key highlight of the presentation is Cyagen’s proprietary TurboKnockout^® platform, the latest advancement in ES-cell based gene targeting technology. TurboKnockout^® enables generation of complex genomically modified mouse models in as little as 6 months—four to six months faster than traditional methods.

Lastly, the presentation highlights Cyagen’s genomically humanized mouse model programs – HUGO-GT™ and HUGO-Ab™ – in which the mouse gene is replaced with the full-length human gene, including exons, introns, and untranslated regions (UTRs). Dr. Ouyang discusses the applications of these models in biomedical research, particularly in studies related to cancer and gene therapy for rare diseases.

Seminar Details

North Carolina State University

Polk Hall Room 125

April 16, 2025

11:45 AM - 12:35 PM

▶▶ Light refreshments/Complimentary lunch provided for registered attendees

Or Join via Zoom: Link to Join Now >>

Meeting ID: 944 3355 9347 Passcode: 934420

Who Should Attend?

• Researchers in oncology, immunology, and neuroscience
• Pharmaceutical scientists involved in drug development
• Clinical researchers focused on gene therapy
• Geneticists interested in rare diseases
• Students in biomedical fields
• Industry professionals in biotech

Speaker

Marvin Yingbin Ouyang, MD, PhD

Executive Vice President and Chief Scientific Officer, Cyagen

Before joining Cyagen in 2012, Dr. Ouyang served as a senior scientist at Oklahoma Medical Research Foundation, Thios Pharmaceuticals in the United States, and as Group Leader of the Molecular Biology Department of Taconic Biosciences. Over the past 20 years, he has committed himself to the custom design and generation of genetically engineered mice. While at Cyagen, he has successfully developed thousands of transgenic and gene knockout/knockin mouse and rat models for the biomedical research and drug discovery communities worldwide. He has published many papers in high-level academic journals such as PNAS and JBC; his technical services have been directly cited by Nature and other international journals hundreds of times.

About Cyagen

Founded in 2006, Cyagen is a leading provider of custom cell and animal models, as well as comprehensive CRO services to accelerate preclinical research and drug development. We offer a one-stop platform for model generation, including phenotyping, functional validation, and pathological analysis.

Our proprietary genetic modification technologies—Targeted Gene Editing-Pro, TurboKnockout, and PiggyBac-on-BAC transgenics—enable efficient disease model development, while our Knockout Catalog Models feature over 16,000 ready-to-use KO/cKO mouse strains. Cyagen’s innovative platforms include fully humanized genomic ortholog (HUGO) Mice for Gene Therapy (HUGO-GT) and Antibody Discovery (HUGO-Ab), AI platforms to accelerate preclinical cell and gene therapy (CGT) research, AAV discovery,  and drug efficacy studies.

With expertise covering custom model development, CGT, rare disease research, and gene therapy, Cyagen supports global scientists with cutting-edge tools and services. Contact us for a free consultation. Contact us for a free consultation.

About HUGO-GT™ Mouse Models

The Humanized Genomic Ortholog for Gene Therapy (HUGO-GT™) mouse model offers a higher degree of humanization compared to traditional models to serve as an effective evaluation platform, especially for gene therapy drugs with high requirements for gene sequence integrity, such as ASO, Targeted Gene Editing, and siRNA.

Our HUGO-GT™ fully humanized genome mice are developed based on the proprietary TurboKnockout-Pro technology to achieve in situ replacement of mouse genes, encompassing a broader range of intervention targets and providing full coverage of pathogenic gene mutation sites-all without patent or ownership disputes. The fully humanized target genes within these models are consistent with the pathogenic genes carried by humans and cover the majority of drug targets, significantly enhancing screening efficiency for various types of preclinical drug experiments.

About HUGO-Ab™ Mouse Models

The HUGO-Ab™ Humanized Antibody Discovery Platform developed by Cyagen offers a revolutionary approach to therapeutic antibody discovery. This advanced mouse model has been humanized to contain immunoglobulin variable regions, promoting a robust and diverse immune response. The platform supports antibody functional pharmacologic evaluation, including in vitro and in vivo efficacy assessments, and is optimized for generating high-affinity, fully human antibodies suitable for drug development. By leveraging cutting-edge technologies, HUGO-Ab™ aims to meet the growing demand for innovative in vivo models in cancer and autoimmune disease research, ensuring low immunogenicity and exceptional binding affinity in antibody screening processes. Based on the HUGO-Ab™ humanized antibody mouse model and antibody discovery platform, we look forward to collaborating with researchers to fully leverage the drug-like properties optimized in the mouse model and advance the development of human antibodies.